Elisabeth Silkenstedt

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients.

First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients.

Journal: Hematological oncology

Published: March 23, 2025

Development and implementation of novel liquid biopsy NGS panels via the OncNGS precommercial procurement (PCP) initiative.

Development and implementation of novel liquid biopsy NGS panels via the OncNGS precommercial procurement (PCP) initiative.

Journal: ESMO open

Published: January 27, 2025

To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL.

To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 07, 2024

BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma.

BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma.

Journal: Blood advances

Published: November 13, 2024

Treatment of relapsed/refractory MCL.

Treatment of relapsed/refractory MCL.

Journal: Blood

Published: March 15, 2024

Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.

Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.

Journal: Blood advances

Published: February 23, 2024

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Journal: Leukemia

Published: December 20, 2023

Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches.

Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches.

Journal: Hematological oncology

Published: March 28, 2023

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.

Journal: Annals of hematology

Published: March 08, 2023

Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.

Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.

Journal: Hematological oncology

Published: January 20, 2023

Aggressive lymphoma (DLBCL, MCL) - what's new?

Aggressive lymphoma (DLBCL, MCL) - what's new?

Journal: Deutsche medizinische Wochenschrift (1946)

Published: November 01, 2022

B-cell non-Hodgkin lymphomas.

B-cell non-Hodgkin lymphomas.

Journal: Lancet (London, England)

Published: July 29, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026